Trial Condition(s):
Erectile Dysfunction
Study Evaluating the Efficacy and Safety of flexible-dose Vardenafil in subjects with erectile dysfunction
Bayer Identifier:
100497
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Study to investigate the efficacy and safety of Vardenafil
Inclusion Criteria
- Men >/= 18 years of age, with 6 months or longer diagnosis of ED as defined by NIH Consensus statement, - History of unresponsiveness to sildenafil - Stable sexual relationship for > 6 month.
Exclusion Criteria
- Primary hypoactive sexual desire - History of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month - Nitrate therapy - Other exclusion criteria apply according to the US Product Information
Trial Summary
Enrollment Goal
463
Trial Dates
Phase
3
Could I receive a placebo?
Yes
Products
Levitra (Vardenafil, BAY38-9456)
Accepts Healthy Volunteers
No
Where to Participate
Locations
| Locations |
|---|
Trial Design
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Randomized
Blinding:
Double Blind
Assignment:
Parallel Assignment
Trial Arms:
2
Primary Outcome
- Sexual Encounter Profile Question 2Timeframe: 12 weeks
Secondary Outcome
- Sexual Encounter Profile Question 3Timeframe: 12 weeks
- Internation Index of Erectile Function-Erectile Function domainTimeframe: 12 weeks
- Safety and tolerabilityTimeframe: 12 weeks
Additional Information
Copyright © Bayer
Powered by
